scholarly journals Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives

2015 ◽  
Vol 32 ◽  
pp. 56-60 ◽  
Author(s):  
Erica Lessem ◽  
Helen Cox ◽  
Colleen Daniels ◽  
Jennifer Furin ◽  
Lindsay McKenna ◽  
...  
Keyword(s):  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Community Perspectives

scholarly journals Drug-resistant tuberculosis patient care journeys in South Africa: a pilot study using routine laboratory data

2020 ◽  
Vol 24 (1) ◽  
pp. 83-91
Author(s):  
J. Hill ◽  
L. Dickson-Hall ◽  
A. D. Grant ◽  
C. Grundy ◽  
J. Black ◽  
...  
Keyword(s):  
South Africa ◽  
Rural Areas ◽  
Laboratory Data ◽  
Healthcare Services ◽  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Western Cape ◽  
Routine Laboratory ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis

SETTING: Thirteen districts in Eastern Cape (EC), KwaZulu-Natal (KZN) and Western Cape (WC) Provinces, South Africa.OBJECTIVE: To pilot a methodology for describing and visualising healthcare journeys among drug-resistant tuberculosis (DR-TB) patients using routine laboratory records.DESIGN: Laboratory records were obtained for 195 patients with laboratory-detected rifampicin-resistant TB (RR-TB) during July–September 2016. Health facility visits identified from these data were plotted to visualise patient healthcare journeys. Data were verified by facility visits.RESULTS: In the 9 months after the index RR-TB sample was collected, patients visited a mean of 2.3 health facilities (95% CI 2.1–2.6), with 9% visiting ≥4 facilities. The median distance travelled by patients from rural areas (116 km, interquartile range [IQR] 50–290) was greater than for urban patients (51 km, IQR 9–140). A median of 21% of patient's time was spent under the care of primary healthcare facilities: this was respectively 6%, 37% and 39% in KZN, EC and WC. Journey patterns were generally similar within districts. Some reflected a semi-centralised model of care where patients were referred to regional hospitals; other journeys showed greater involvement of primary care.CONCLUSION: Routine laboratory data can be used to explore DR-TB patient healthcare journeys and show how the use of healthcare services for DR-TB varies in different settings.

scholarly journals Ketahanan hidup 2 tahun pasien tuberkulosis resisten obat di RS. Moewardi Surakarta tahun 2010-2014

2017 ◽  
Vol 33 (8) ◽  
pp. 371
Author(s):  
Artika Fristi Firnawati ◽  
Riris Andono Ahmad ◽  
Heni Retnowulan
Keyword(s):  
Survival Rate ◽  
Cox Regression ◽  
Tuberculosis Patient ◽  
Bivariate Analysis ◽  
Hiv Positive ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Tuberculosis Patients ◽  
Resistant Tuberculosis ◽  
Regression Test

Two year survival of drug resistant tuberculosis patients in Moewardi hospital in Surakarta in 2010-2014PurposeThe purpose of this study was to determine the two year survival rate and predictor factors of mortality in drug resistant tuberculosis patients during treatment at the Moewardi Hospital in Surakarta.MethodsThis research was a retrospective cohort study of 250 drug resistant tuberculosis patients receiving treatment in the Moewardi Hospital in January 2011-September 2014. Data were analyzed using survival analysis to find factors affecting the 2 year survival. Our variables were demographic factors, disease characteristics and treatment history. We used Cox regression test with 5% significance level.Results2-year survival rates of drug resistant patients was 74.82%. age, the type of patient, HIV status, side effects of medications and culture conversion were significant to survival rate in bivariate analysis. Cox regression test showed that aged ≥ 40 years (HR 3.221; 95% CI 1.037 to 10.001) and have HIV-positive status (HR 18.086; 95% CI 1.958 to 167.073) were related with reduction of two year survival rate in drug resistant tuberculosis patient. ConclusionAge above 40 years old and HIV positive status for drug-resistant tuberculosis patients may accelerate their death. The screening of HIV in drug resistant tuberculosis patients is needed in order to increase two year survival rate of patients during treatment.

scholarly journals A Case Report on Reversible Toxic Optic Neuropathy on Long Term Treatment of Linezolid in Extensively Drug-Resistant Tuberculosis Patient

2021 ◽  
pp. 7-11
Author(s):  
Sunil Kardani ◽  
Rajesh Hadia ◽  
Ashish Shah ◽  
Ghanshyam Parmar ◽  
Rajesh Maheshwari ◽  
...  
Keyword(s):  
Optic Neuropathy ◽  
Term Treatment ◽  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Toxic Optic Neuropathy ◽  
Resistant Tuberculosis ◽  
Long Term Treatment ◽  
Long Time ◽  
Drug Regimens

We describe a case of Linezolid-induced severe toxic optic neuropathy in a patient with drug-resistant tuberculosis. Linezolid produced severe toxic optic neuropathy in some who used it for a long time. To the best of our knowledge, the optic neuropathy was completely reversed after omitting Linezolid which is one of the effective drug regimens in his prescription, with significant improvements in eye vision.

scholarly journals Ototoxic effect of anti-tubercular treatment on multi-drug resistant tuberculosis patient

2019 ◽  
Vol 6 (1) ◽  
pp. 8
Author(s):  
Sachin Jain ◽  
M. Aftab ◽  
Shivendra Pratap Singh ◽  
Abhishek Kumar Dubey ◽  
Ved Prakash Upadhyay ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Pure Tone Audiometry ◽  
Control Program ◽  
Tuberculosis Patient ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Multi Drug Resistant Tuberculosis ◽  
Mdr Tb

<p class="abstract"><strong>Background:</strong> Multi-drug resistant tuberculosis (MDR-TB) is defined as tuberculosis caused by <em>Mycobacterium tuberculosis</em> resistant in vitro to the effects of isoniazid and rifampicin, with or without resistance to any other drugs. Regimen for MDR-TB<strong> </strong>comprises of 6 drugs - kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol and cycloserine during 6-9 months of the intensive phase and 4 drugs levofloxacin, ethionamide, ethambutol and cycloserine during the 18 months of the continuation phase. The aim of our study was to document the incidence and severity of ototoxicity in MDR-TB patient receiving category IV treatment under the revised national tuberculosis control program.</p><p class="abstract"><strong>Methods:</strong> Prospective cohort study was carried out on proven case of MDR-TB patients. Total 61 patients were evaluated for the development of ototoxicity, for a period of one year. First three months of study pre-treatment baseline audiogram were recorded by pure tone audiometry, and repeat audiogram was done after six months and nine months.  </p><p class="abstract"><strong>Results:</strong> Out of 61 patients 21 patients developed ototoxicity with incidence of 34.42%. Incidence of high frequency hearing loss was 21.31% and flat loss was 13.11%.</p><p class="abstract"><strong>Conclusions:</strong> MDR-TB patients, due to effect of aminoglycoside may develop mild to severe degree of hearing loss. As hearing loss in these patients is permanent, careful audiological monitoring should be done regularly.</p><p class="abstract"> </p>

Sign in / Sign up

Export Citation Format

Share Document